Protocol ID
|
Trial Title
|
|---|
| VICC THO 0206, ID01-604; NCT00043823 |
A Phase I/II Clinical Trial of Bevacizumab and Erlotinib in Patients with Locally Advanced or Metastatic Non-Squamous Cell NSCLC in Patients Who Have Been Previously Treated |
| AVF2938g, UCLA-0404042, GENENTECH-AVF2938G; NCT00081614 |
A Phase II, Multicenter, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Tarceva (Erlotinib Hydrochloride) in Combination With Avastin (Bevacizumab) Versus Avastin Alone for Treatment of Metastatic Renal Cell Carcinoma |
| CDR0000361807; DFCI-03083; NCT00083031 |
Metronomic Chemotherapy in Combination With Bevacizumab for Advanced Breast Cancer |
| 2003-0520; NCT00081861 |
A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
| MDA-ID-02227; MILLENNIUM-MDA-ID-02227; CDR0000355822; NCT00082680 |
Phase I Study of Weekly Intravenous PS-341 Plus Mitoxantrone in Patients With Advanced Androgen-Independent Prostate Cancer (Al-PCa) |
| CDR0000360816; MCV-MCC-6413; NCI-6413; NCT00082784 |
Phase I Trial of Bortezomib and Alvocidib in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms |
| UARK 2001-37; NCT00083460 |
UARK 2001-37, A Phase I Exploratory Study of Combination PS-341 and Thalidomide in Refractory Multiple Myeloma |
| CDR0000257580; UCLA-0109024; BCIRG-007; ROCHE-UCLA-0109024; GENENTECH-UCLA-0109024; NCI-G02-2116; NCT00047255 |
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification |
| CDR0000390235; UCLA-0401054-01; MILLENNIUM-M34103-061; NCT00093769 |
A Phase II Study of VELCADE With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma |
| 2938; H3E-MC-JMDB; NCT00087711 |
A Phase III Clinical Trial of Pemetrexed and Cisplatin Compared to Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT00077961, CAM.NHL233 |
Phase I/II Study of Rituximab Plus Campath in Patients with Previously Treated Relapsed or Refractory Low-Grade Follicular, CD20-Positive, B-Cell Non-Hodgkin's Lymphoma |
| CDR0000450765, ECOG-E1904, NCT00262925 |
Phase II Study of Methotrexate, Vincristine, Asparaginase and Dexamethasone (MOAD), in Combination With Alemtuzumab, in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
| D791AC00007; NCT00322452 |
Open Label, Randomised, Parallel Group, Multicenter, Phase III Trial to Assess Efficacy, Safety and Tolerability of Gefitinib (Iressa) versus Carboplatin/Paclitaxel as First Line Treatment in Selected Patients with Stage IIIb/IV NSCLC in Asia |
| MCC-14662; NCT00365599 |
Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination With Tamoxifen for Patients With Advanced Breast Cancer Who Have Failed Prior Anti-Hormonal Therapy. |
